All lobbying filings

INNOVATIVE FEDERAL STRATEGIES, LLC

Lobbying for ACURX PHARMACEUTICALS, INC. · biopharmaceutical company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$30,000.00

What the client paid this registrant for the period.

Client based in

New York

Official filing document

Government bodies contacted 3

HOUSE OF REPRESENTATIVES
Navy, Dept of
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 4026
POST Act of 2025
S 2572
Department of Defense Appropriations Act, 2026
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026

Lobbying activity 2

Defense

H.R.3838/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.

Budget/Appropriations

H.R.4026/S.2572, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.5304/S.2587, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.